MCL1 and cancer: In recent years, many new development of Mcl-1 inhibitors have been designed and entered clinical trial for different types of cancer as mono or combined treatment with Venetoclax (AstraZeneca, 2022) (AbbVie, 2021) (Institut de Recherches Internationales Servier, 2022).